Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;109:904-910
Published online before print February 16, 2004, doi: 10.1161/01.CIR.0000112596.06954.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
109/7/904    most recent
01.CIR.0000112596.06954.00v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Irukayama-Tomobe, Y.
Right arrow Articles by Yamaguchi, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Irukayama-Tomobe, Y.
Right arrow Articles by Yamaguchi, I.
Related Collections
Right arrow Physiological and pathological control of gene expression

(Circulation. 2004;109:904-910.)
© 2004 American Heart Association, Inc.


Basic Science Reports

Endothelin-1–Induced Cardiac Hypertrophy Is Inhibited by Activation of Peroxisome Proliferator–Activated Receptor-{alpha} Partly Via Blockade of c-Jun NH2-Terminal Kinase Pathway

Yoko Irukayama-Tomobe, PhD; Takashi Miyauchi, MD, PhD; Satoshi Sakai, MD, PhD; Yoshitoshi Kasuya, PhD; Takehiro Ogata, MD; Masakatsu Takanashi, PhD; Motoyuki Iemitsu, PhD; Tatsuhiko Sudo, PhD; Katsutoshi Goto, PhD; Iwao Yamaguchi, MD, PhD

From the Cardiovascular Division, Department of Internal Medicine, Institute of Clinical Medicine (Y.I.-T., T.M., S.S., T.O., M.T., M.I., I.Y.) and Department of Pharmacology, Institute of Basic Medical Sciences (K.G.), University of Tsukuba, Tsukuba, Ibaraki; Graduate School of Medicine, Chiba University (Y.K.), Inohana, Ciba; and The Institute of Physical and Chemical Research (RIKEN) (T.S.), Wako, Saitama, Japan.

Correspondence to Takashi Miyauchi, MD, PhD, Cardiovascular Division, Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan. E-mail t-miyauc{at}md.tsukuba.ac.jp

Received April 18, 2002; de novo received November 21, 2002; revision received October 15, 2003; accepted October 16, 2003.

Background— Peroxisome proliferator-activated receptor-{alpha} (PPAR-{alpha}) is a lipid-activated nuclear receptor that negatively regulates the vascular inflammatory gene response by interacting with transcription factors, nuclear factor-{kappa}B, and AP-1. However, the roles of PPAR-{alpha} activators in endothelin (ET)-1–induced cardiac hypertrophy are not yet known.

Methods and Results— First, in cultured neonatal rat cardiomyocytes, a PPAR-{alpha} activator, fenofibrate (10 µmol/L), and PPAR-{alpha} overexpression markedly inhibited the ET-1–induced increase in protein synthesis. Second, fenofibrate markedly inhibited ET-1–induced increase in c-Jun gene expression and phosphorylation of c-Jun and JNK. These results suggest that this PPAR-{alpha} activator interferes with the formation and activation of AP-1 protein induced by ET-1 in cardiomyocytes. Third, fenofibrate significantly inhibited the increase of ET-1 mRNA level by ET-1, which was also confirmed by luciferase assay. Electrophoretic mobility shift assay revealed that fenofibrate significantly decreased the ET-1–stimulated or phorbol 12-myristate 13-acetate–stimulated AP-1 DNA binding activity, and the nuclear extract probe complex was supershifted by anti-c-Jun antibody. Fourth, 24 hours after aortic banding (AB) operation, fenofibrate treatment significantly inhibited left ventricular hypertrophy and hypertrophy-related gene expression pattern (ET-1, brain natriuretic peptide, and ß-myosin heavy chain mRNA) in AB rats.

Conclusions— These results suggest that PPAR-{alpha} activation interferes with the signaling pathway of ET-1–induced cardiac hypertrophy through negative regulation of AP-1 binding activity, partly via inhibition of the JNK pathway in cultured cardiomyocytes. We also revealed that fenofibrate treatment inhibited left ventricle hypertrophy and phenotypic changes in cardiac gene expression in AB rats in vivo.


Key Words: endothelin • hypertrophy • signal transduction




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Iemitsu, N. Shimojo, S. Maeda, Y. Irukayama-Tomobe, S. Sakai, T. Ohkubo, Y. Tanaka, and T. Miyauchi
The benefit of medium-chain triglyceride therapy on the cardiac function of SHRs is associated with a reversal of metabolic and signaling alterations
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H136 - H144.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. P. Alibin, M. A. Kopilas, and H. D. I. Anderson
Suppression of Cardiac Myocyte Hypertrophy by Conjugated Linoleic Acid: ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS {alpha} AND {gamma}
J. Biol. Chem., April 18, 2008; 283(16): 10707 - 10715.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
P. J.H. Smeets, B. E.J. Teunissen, P. H.M. Willemsen, F. A. van Nieuwenhoven, A. E. Brouns, B. J.A. Janssen, J. P.M. Cleutjens, B. Staels, G. J. van der Vusse, and M. van Bilsen
Cardiac hypertrophy is enhanced in PPAR{alpha}-/- mice in response to chronic pressure overload
Cardiovasc Res, April 1, 2008; 78(1): 79 - 89.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
N. K. LeBrasseur, T.-A. S. Duhaney, D. S. De Silva, L. Cui, P. C. Ip, L. Joseph, and F. Sam
Effects of Fenofibrate on Cardiac Remodeling in Aldosterone-Induced Hypertension
Hypertension, September 1, 2007; 50(3): 489 - 496.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
N. Shimojo, S. Jesmin, S. Zaedi, T. Otsuki, S. Maeda, N. Yamaguchi, K. Aonuma, Y. Hattori, and T. Miyauchi
Contributory role of VEGF overexpression in endothelin-1-induced cardiomyocyte hypertrophy
Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H474 - H481.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
T. Nakamachi, T. Nomiyama, F. Gizard, E. B. Heywood, K. L. Jones, Y. Zhao, L. Fuentes, K. Takebayashi, Y. Aso, B. Staels, et al.
PPAR{alpha} Agonists Suppress Osteopontin Expression in Macrophages and Decrease Plasma Levels in Patients With Type 2 Diabetes
Diabetes, June 1, 2007; 56(6): 1662 - 1670.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
S. Jesmin, S. Zaedi, N. Shimojo, M. Iemitsu, K. Masuzawa, N. Yamaguchi, C. N. Mowa, S. Maeda, Y. Hattori, and T. Miyauchi
Endothelin antagonism normalizes VEGF signaling and cardiac function in STZ-induced diabetic rat hearts
Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1030 - E1040.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y.-J. Liang, L.-P. Lai, B.-W. Wang, S.-J. Juang, C.-M. Chang, J.-G. Leu, and K.-G. Shyu
Mechanical stress enhances serotonin 2B receptor modulating brain natriuretic peptide through nuclear factor-{kappa}B in cardiomyocytes
Cardiovasc Res, November 1, 2006; 72(2): 303 - 312.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
N. Shimojo, S. Jesmin, S. Zaedi, S. Maeda, M. Soma, K. Aonuma, I. Yamaguchi, and T. Miyauchi
Eicosapentaenoic acid prevents endothelin-1-induced cardiomyocyte hypertrophy in vitro through the suppression of TGF-beta1 and phosphorylated JNK
Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H835 - H845.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
M. Iemitsu, S. Maeda, S. Jesmin, T. Otsuki, Y. Kasuya, and T. Miyauchi
Activation pattern of MAPK signaling in the hearts of trained and untrained rats following a single bout of exercise
J Appl Physiol, July 1, 2006; 101(1): 151 - 163.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
N. Shimojo, S. Jesmin, S. Zaedi, M. Soma, T. Kobayashi, S. Maeda, I. Yamaguchi, K. Goto, and T. Miyauchi
Effect of eicosapentaenoic Acid on the different endothelin system components in endothelin-1-induced hypertrophied cardiomyocytes.
Experimental Biology and Medicine, June 1, 2006; 231(6): 888 - 892.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
N. Shimojo, S. Jesmin, S. Zaedi, M. Soma, T. Kobayashi, S. Maeda, I. Yamaguchi, K. Goto, and T. Miyauchi
EPA Effect on NOS Gene Expression and on NO Level in Endothelin-1-Induced Hypertrophied Cardiomyocytes.
Experimental Biology and Medicine, June 1, 2006; 231(6): 913 - 918.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. Asai, K. Okumura, R. Takahashi, H. Matsui, Y. Numaguchi, H. Murakami, R. Murakami, and T. Murohara
Combined therapy with PPAR{alpha} agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency
Cardiovasc Res, June 1, 2006; 70(3): 566 - 577.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
F. He, J. Li, Y. Mu, R. Kuruba, Z. Ma, A. Wilson, S. Alber, Y. Jiang, T. Stevens, S. Watkins, et al.
Downregulation of Endothelin-1 by Farnesoid X Receptor in Vascular Endothelial Cells
Circ. Res., February 3, 2006; 98(2): 192 - 199.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
H. B. Tanowitz, H. Huang, L. A. Jelicks, M. Chandra, M. L. Loredo, L. M. Weiss, S. M. Factor, V. Shtutin, S. Mukherjee, R. N. Kitsis, et al.
Role of Endothelin 1 in the Pathogenesis of Chronic Chagasic Heart Disease
Infect. Immun., April 1, 2005; 73(4): 2496 - 2503.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. N. Petrashevskaya and A. Schwarz
Peroxisome proliferator-activated receptor {beta}/{delta}: a new antihypertrophic drug target?
Cardiovasc Res, March 1, 2005; 65(4): 770 - 771.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Planavila, R. Rodriguez-Calvo, M. Jove, L. Michalik, W. Wahli, J. C. Laguna, and M. Vazquez-Carrera
Peroxisome proliferator-activated receptor {beta}/{delta} activation inhibits hypertrophy in neonatal rat cardiomyocytes
Cardiovasc Res, March 1, 2005; 65(4): 832 - 841.
[Abstract] [Full Text] [PDF]